A First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06741086, an anti-TFPI Monoclonal Antibody, in Healthy Volunteers.
CONCLUSIONS: Single doses of PF-06741086 at multiple dose levels were safe and well tolerated in a healthy adult male population. The safety, PK and PD data from this study support progression to a multiple dose study in hemophilia patients. This article is protected by copyright. All rights reserved.
PMID: 29908043 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Cardinal M, Kantaridis C, Zhu T, Sun P, Pittman DD, Murphy JE, Arkin S Tags: J Thromb Haemost Source Type: research
More News: Drugs & Pharmacology | Electrocardiogram | Haemophilia | Hematology | Hemophilia | Laboratory Medicine | Study | Thrombosis